A much larger follow-up phase 2b study (registration number:NCT04680637) has recently initiated recruitment of a cohort of 320 SLE patients and comparing treatment efficacy between patients with high IL-2 levels and those with normal physiological IL-2 concentrations will be of interest. The gene discussed is IL2; the disease is systemic lupus erythematosus.